MX9701327A - Metodos para inhibir el cancer endometrial. - Google Patents
Metodos para inhibir el cancer endometrial.Info
- Publication number
- MX9701327A MX9701327A MX9701327A MX9701327A MX9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A MX 9701327 A MX9701327 A MX 9701327A
- Authority
- MX
- Mexico
- Prior art keywords
- endometrial cancer
- methods
- inhibiting endometrial
- inhibiting
- hexamethyleneimino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29385394A | 1994-08-22 | 1994-08-22 | |
| PCT/US1995/010651 WO1996005833A1 (en) | 1994-08-22 | 1995-08-21 | Methods of inhibiting endometrial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9701327A true MX9701327A (es) | 1997-05-31 |
Family
ID=23130867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9701327A MX9701327A (es) | 1994-08-22 | 1995-08-21 | Metodos para inhibir el cancer endometrial. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0777476A4 (fi) |
| JP (1) | JPH10504824A (fi) |
| KR (1) | KR970705387A (fi) |
| AU (1) | AU688112B2 (fi) |
| CA (1) | CA2198119A1 (fi) |
| CZ (1) | CZ51897A3 (fi) |
| FI (1) | FI970717A (fi) |
| HU (1) | HUT76890A (fi) |
| IL (1) | IL115022A (fi) |
| MX (1) | MX9701327A (fi) |
| MY (1) | MY113757A (fi) |
| NO (1) | NO970783L (fi) |
| NZ (1) | NZ292017A (fi) |
| RU (1) | RU2161964C2 (fi) |
| TW (1) | TW404834B (fi) |
| WO (1) | WO1996005833A1 (fi) |
| ZA (1) | ZA956994B (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856340A (en) * | 1995-02-28 | 1999-01-05 | Eli Lilly And Company | Method of treating estrogen dependent cancers |
| US7005428B1 (en) | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| KR20160066490A (ko) * | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
| CN115825414B (zh) * | 2023-01-09 | 2023-04-25 | 中国医学科学院北京协和医院 | 血液或尿液代谢标志物及其在子宫内膜癌早筛中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| US5482949A (en) * | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
| CA2160135A1 (en) * | 1993-04-07 | 1994-10-13 | Donald P. Mcdonnell | Method for screening for receptor agonists |
| KR950010891A (ko) * | 1993-10-15 | 1995-05-15 | 피터 지. 스트링거 | 내성 종양을 치료하는 방법 |
| ZA956988B (en) * | 1994-08-22 | 1997-02-21 | Lilly Co Eli | Methods of inhibiting primary endometrial hyperplasia. |
| US5843964A (en) * | 1994-09-22 | 1998-12-01 | Eli Lilly And Company | Methods of inhibiting endometrial mitoses |
-
1995
- 1995-08-21 RU RU97104160/14A patent/RU2161964C2/ru active
- 1995-08-21 CZ CZ97518A patent/CZ51897A3/cs unknown
- 1995-08-21 HU HU9701499A patent/HUT76890A/hu unknown
- 1995-08-21 MX MX9701327A patent/MX9701327A/es unknown
- 1995-08-21 JP JP8508265A patent/JPH10504824A/ja active Pending
- 1995-08-21 AU AU33700/95A patent/AU688112B2/en not_active Ceased
- 1995-08-21 KR KR1019970701095A patent/KR970705387A/ko not_active Application Discontinuation
- 1995-08-21 WO PCT/US1995/010651 patent/WO1996005833A1/en not_active Application Discontinuation
- 1995-08-21 MY MYPI95002449A patent/MY113757A/en unknown
- 1995-08-21 ZA ZA9506994A patent/ZA956994B/xx unknown
- 1995-08-21 IL IL11502295A patent/IL115022A/xx not_active IP Right Cessation
- 1995-08-21 TW TW084108700A patent/TW404834B/zh not_active IP Right Cessation
- 1995-08-21 EP EP95930243A patent/EP0777476A4/en not_active Withdrawn
- 1995-08-21 CA CA002198119A patent/CA2198119A1/en not_active Abandoned
- 1995-08-21 NZ NZ292017A patent/NZ292017A/en unknown
-
1997
- 1997-02-20 FI FI970717A patent/FI970717A/fi unknown
- 1997-02-20 NO NO970783A patent/NO970783L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2161964C2 (ru) | 2001-01-20 |
| TW404834B (en) | 2000-09-11 |
| WO1996005833A1 (en) | 1996-02-29 |
| FI970717A0 (fi) | 1997-02-20 |
| MY113757A (en) | 2002-05-31 |
| HUT76890A (en) | 1997-12-29 |
| AU3370095A (en) | 1996-03-14 |
| IL115022A0 (en) | 1998-06-15 |
| JPH10504824A (ja) | 1998-05-12 |
| KR970705387A (ko) | 1997-10-09 |
| CZ51897A3 (en) | 1997-06-11 |
| EP0777476A4 (en) | 1999-06-23 |
| EP0777476A1 (en) | 1997-06-11 |
| ZA956994B (en) | 1997-02-21 |
| IL115022A (en) | 2000-07-31 |
| NO970783D0 (no) | 1997-02-20 |
| NZ292017A (en) | 2000-07-28 |
| NO970783L (no) | 1997-02-20 |
| FI970717A (fi) | 1997-02-20 |
| AU688112B2 (en) | 1998-03-05 |
| CA2198119A1 (en) | 1996-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9701329A (es) | Metodos para la inhibicion de la replicacion viral. | |
| MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
| AU7578794A (en) | Methods for inhibiting endometriosis | |
| MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
| MX9701334A (es) | Metodos para inhibir la degeneracion de protesis oseas. | |
| MX9709466A (es) | Medicamento para inhibir el melanoma. | |
| MX9701327A (es) | Metodos para inhibir el cancer endometrial. | |
| MX9702148A (es) | Metodos para inhibir la mitosis endometrial. | |
| MX9701333A (es) | Metodos para inhibir el daño neuronal. | |
| MY113406A (en) | Methods of inhibiting physiological conditions associated with an excess of bradykinin | |
| MX9701332A (es) | Metodos para curar y reparar fracturas oseas. | |
| MX9701359A (es) | Metodos para la inhibicion de la hiperplasia endometrial primaria. | |
| MX9701331A (es) | Metodos para mantener los dientes y los huesos bucales. | |
| MX9701328A (es) | Metodos de reduccion de la cicatrizacion en la curacion de heridas. | |
| MX9705940A (es) | Metodos y composiciones para inhibir los efectos de la interleucina 6. | |
| MX9706520A (es) | Metodos para inhibir el cancer de ovario. | |
| MX9706072A (es) | Metodos de inhibicion de la adhesion celula-celula. | |
| MX9709536A (es) | Metodo para reducir el factor de transcripcion bef-1. | |
| MX9705215A (es) | Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento. | |
| MX9806036A (es) | Compuestos para inhibir tumores en el colon. | |
| MX9705537A (es) | Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente. | |
| MX9709651A (es) | Metodos para modulacion del factor de transcripcion nf-kb. | |
| MX9705697A (es) | Metodos para reducir los niveles de calcio del suero. | |
| MX9702853A (es) | Metodos para inhibir condiciones asociadas con el neuropeptido "y". |